Composés arylquinoléine et analogues de ceux-ci et utilisation de ces derniers pour traiter le cancer

Arylquinoline and analog compounds and use thereof to treat cancer

Abstract

The subject technology relates to arylquinoline compounds and their use for treating cancer or cancer metastasis. The compounds of the subject technology promote cells to secrete a pro-apoptotic tumor suppressor, i.e., prostate apoptosis response-4 (Par-4), which in turn promote apoptosis in cancer cells or metastatic cells.
La technologie de la présente invention porte sur des composés arylquinoléine et leur utilisation pour traiter un cancer ou une métastase de cancer. Les composés de la technologie de la présente invention incitent des cellules à sécréter un suppresseur de tumeur pro-apoptotique, à savoir la protéine pro-apoptotique prostatique (Par-4), qui, à son tour, favorise l'apoptose dans des cellules cancéreuses ou des cellules métastatiques.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (2)

    Publication numberPublication dateAssigneeTitle
    US-2004077644-A1April 22, 2004Marc Chapdelaine, Lucius Kemp, Mccauley JohnN-type calcium channel antagonists for the treatment of pain
    WO-2009127417-A1October 22, 2009MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.Quinoline derivatives as axl kinase inhibitors

NO-Patent Citations (3)

    Title
    BURIKHANOV, R. ET AL.: "Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis", NATURE CHEMICAL BIOLOGY, vol. 10, no. 11, 14 September 2014 (2014-09-14), pages 924 - 926
    GURUMURTHY, S. ET AL.: "Par-4 inducible apoptosis in prostate cancer cells", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 91, no. 3, 2004, pages 504 - 512, XP002426933, DOI: doi:10.1002/jcb.20000
    LAHAT, G. ET AL.: "Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies", PLOS ONE, vol. 5, no. 4, 2010

Cited By (1)

    Publication numberPublication dateAssigneeTitle
    WO-2016196614-A1December 08, 2016University Of Kentucky Research FoundationChloroquine induction of par-4 and treatment of cancer